These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 10311551)

  • 21. Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France.
    Berchi C; Bouvier V; Réaud JM; Launoy G
    Health Econ; 2004 Mar; 13(3):227-38. PubMed ID: 14981648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India.
    Okonkwo QL; Draisma G; der Kinderen A; Brown ML; de Koning HJ
    J Natl Cancer Inst; 2008 Sep; 100(18):1290-300. PubMed ID: 18780864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methods for conducting systematic reviews of evidence on effectiveness and economic efficiency of interventions to increase screening for breast, cervical, and colorectal cancers.
    Baron RC; Rimer BK; Coates RJ; Kerner J; Mullen PD; Chattopadhyay S; Briss PA;
    Am J Prev Med; 2008 Jul; 35(1 Suppl):S26-33. PubMed ID: 18541185
    [No Abstract]   [Full Text] [Related]  

  • 24. Endoscopic screening for gastric cancer.
    Dan YY; So JB; Yeoh KG
    Clin Gastroenterol Hepatol; 2006 Jun; 4(6):709-16. PubMed ID: 16765306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [New strategy for cancer control].
    Watanabe S
    Gan No Rinsho; 1989 Jan; 35(2):151-5. PubMed ID: 2704122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam.
    Levin CE; Sellors JW
    Cancer; 2002 Apr; 94(8):2312-4; author reply 2314-6. PubMed ID: 12001136
    [No Abstract]   [Full Text] [Related]  

  • 27. Is population screening for colorectal cancer cost-effective?
    Pignone M
    Nat Clin Pract Gastroenterol Hepatol; 2005 Jul; 2(7):288-9. PubMed ID: 16265263
    [No Abstract]   [Full Text] [Related]  

  • 28. Colorectal cancer screening: health impact and cost effectiveness.
    Maciosek MV; Solberg LI; Coffield AB; Edwards NM; Goodman MJ
    Am J Prev Med; 2006 Jul; 31(1):80-9. PubMed ID: 16777546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of screening for colorectal cancer.
    Budenholzer B; Welch HG
    Ann Intern Med; 2001 Aug; 135(3):219. PubMed ID: 11487493
    [No Abstract]   [Full Text] [Related]  

  • 30. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam.
    Suba EJ; Nguyen CH; Nguyen BD; Raab SS;
    Cancer; 2001 Mar; 91(5):928-39. PubMed ID: 11251944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Screening of colorectal cancer in Finland and analysis of its cost-effectiveness].
    Malila N; Anttila A; Elovainio L; Hakulinen T; Järvinen H; Paimela H; Pikkarainen P; Rautalahti M; Hakama M
    Duodecim; 2003; 119(12):1115-23. PubMed ID: 12868357
    [No Abstract]   [Full Text] [Related]  

  • 32. Economic evaluation of HIV screening in pregnant women attending antenatal clinics in India.
    Kumar M; Birch S; Maturana A; Gafni A
    Health Policy; 2006 Jul; 77(2):233-43. PubMed ID: 16126300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peutz-Jeghers syndrome and screening for pancreatic cancer.
    Latchford A; Greenhalf W; Vitone LJ; Neoptolemos JP; Lancaster GA; Phillips RK
    Br J Surg; 2006 Dec; 93(12):1446-55. PubMed ID: 17115408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic considerations for the hepatologist.
    Provenzale D
    Hepatology; 1999 Jun; 29(6 Suppl):13S-17S. PubMed ID: 10386077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. From cost-effectiveness information to decision-making on liquid-based cytology: Mind the gap.
    Legood R; Wolstenholme J; Gray A
    Health Policy; 2009 Feb; 89(2):193-200. PubMed ID: 18619702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Who benefits from lipid-screening programmes?
    Crick JC
    Br J Hosp Med; 1992 Jul 29-Sep 1; 48(3-4):198. PubMed ID: 1422539
    [No Abstract]   [Full Text] [Related]  

  • 37. Cost-benefit analysis: probabilities and provisos.
    Rothenberg R
    Sex Transm Dis; 1983; 10(4):216-8. PubMed ID: 6420910
    [No Abstract]   [Full Text] [Related]  

  • 38. Cost-benefit impact on cancer screening.
    Humphrey LJ
    Semin Surg Oncol; 1989; 5(3):205-10. PubMed ID: 2500695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Principles of cancer screening.
    MacLean CD
    Med Clin North Am; 1996 Jan; 80(1):1-14. PubMed ID: 8569290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Digestive diseases and health economics].
    Kobayashi Y
    Nihon Shokakibyo Gakkai Zasshi; 2001 Dec; 98(12):1335-40. PubMed ID: 11808098
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.